Global Tuberculosis (TB)
TB in the United States reflects the global reality. TB is one of the most common infectious diseases worldwide. While significant progress has been made toward the elimination of TB in the United States, this disease remains an urgent public health problem in many other parts of the world.
- In 2013, 65% of all TB cases and 90% of multidrug–resistant TB cases in the United States occurred among people born in other countries.
- Nearly 50% of these individuals were born in just five countries
Many of CDC’s global TB control activities are focused in these high-burden and origin countries. Investing in TB control in high-burden settings reduces TB cases in the United States, costs less than screening at U.S. entry points, and saves funds that would be spent treating TB disease in the U.S.
CDC collaborates with other U.S. Government (USG) agencies, local ministries of health (MOH), multilateral organizations, and non-governmental organizations (NGOs) to build strong national TB programs. CDC plays an important role in finding the most effective ways to implement new tools and approaches in resource-limited and high-burden settings through clinical and operations research, technical assistance, program and policy design, demonstration projects, and program monitoring and evaluation. CDC focuses on supporting innovative approaches to screening, diagnosing, case-finding, and curing TB to stop the spread of disease and prevent development of drug resistance.
Learn more about CDC’s Role in Global Tuberculosis Control
CDC’s Division of Tuberculosis Elimination (DTBE) has worked in every region of the world, providing technical assistance and participating in research collaborations to improve TB control. Significant programmatic and research collaborations are ongoing in Botswana, Cambodia, China, Guyana, Ethiopia, Haiti, India, Kenya, Lesotho, Mexico, Mozambique, Peru, Philippines, Russia, Rwanda, South Africa, Thailand, and Vietnam.